Insider Buying: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Buys 5,997 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 5,997 shares of the business’s stock in a transaction on Friday, October 4th. The stock was purchased at an average price of $6.54 per share, with a total value of $39,220.38. Following the completion of the transaction, the insider now directly owns 2,457,989 shares of the company’s stock, valued at $16,075,248.06. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

enGene Trading Down 3.0 %

NASDAQ:ENGN opened at $9.02 on Friday. The stock has a fifty day simple moving average of $6.71 and a 200 day simple moving average of $9.78. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $398.38 million, a price-to-earnings ratio of -5.24 and a beta of -0.69. enGene Holdings Inc. has a 1-year low of $4.42 and a 1-year high of $43.00.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Sell-side analysts forecast that enGene Holdings Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ENGN. Morgan Stanley restated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene currently has a consensus rating of “Buy” and an average target price of $33.67.

Institutional Trading of enGene

A number of hedge funds have recently modified their holdings of ENGN. Logos Global Management LP grew its holdings in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares in the last quarter. SR One Capital Management LP purchased a new position in enGene during the 2nd quarter valued at about $4,715,000. Janus Henderson Group PLC acquired a new position in shares of enGene in the 1st quarter valued at about $17,095,000. Finally, Altitude Crest Partners Inc. purchased a new stake in shares of enGene in the first quarter worth approximately $2,039,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.